Sangamo Therapeutics (SGMO) Enterprise Value (2016 - 2025)
Historic Enterprise Value for Sangamo Therapeutics (SGMO) over the last 17 years, with Q3 2025 value amounting to -$30.5 million.
- Sangamo Therapeutics' Enterprise Value rose 2212.44% to -$30.5 million in Q3 2025 from the same period last year, while for Sep 2025 it was -$30.5 million, marking a year-over-year increase of 2212.44%. This contributed to the annual value of -$41.9 million for FY2024, which is 726.93% up from last year.
- As of Q3 2025, Sangamo Therapeutics' Enterprise Value stood at -$30.5 million, which was up 2212.44% from -$38.3 million recorded in Q2 2025.
- In the past 5 years, Sangamo Therapeutics' Enterprise Value ranged from a high of -$25.2 million in Q1 2025 and a low of -$588.0 million during Q1 2021
- For the 5-year period, Sangamo Therapeutics' Enterprise Value averaged around -$190.6 million, with its median value being -$100.4 million (2022).
- As far as peak fluctuations go, Sangamo Therapeutics' Enterprise Value plummeted by 6424.92% in 2021, and later skyrocketed by 8058.29% in 2024.
- Over the past 5 years, Sangamo Therapeutics' Enterprise Value (Quarter) stood at -$376.5 million in 2021, then skyrocketed by 73.33% to -$100.4 million in 2022, then surged by 55.0% to -$45.2 million in 2023, then grew by 7.27% to -$41.9 million in 2024, then increased by 27.17% to -$30.5 million in 2025.
- Its last three reported values are -$30.5 million in Q3 2025, -$38.3 million for Q2 2025, and -$25.2 million during Q1 2025.